Back
Windtree Therapeutics 10K Form
Sell
27
WINT
Windtree Therapeutics
Last Price:
0.49
Seasonality Move:
-4.03%
7 Day Trial
ALL ACCESS PASS
$
7
Key Filings
| 2023-11-09 | 10Q | WINT/Windtree Therapeutics Quarterly |
| 2023-08-07 | 10Q | WINT/Windtree Therapeutics Quarterly |
| 2023-05-15 | 10Q | WINT/Windtree Therapeutics Quarterly |
| 2022-11-14 | 10Q | WINT/Windtree Therapeutics Quarterly |
| 2022-08-11 | 10Q | WINT/Windtree Therapeutics Quarterly |
| 2022-05-05 | 10Q | WINT/Windtree Therapeutics Quarterly |
Receive WINT News And Ratings
See the #1 stock for the next 7 days that we like better than WINT
WINT Financial Statistics
Sales & Book Value
| Annual Sales: | $198K |
|---|---|
| Cash Flow: | $-2.34M |
| Price / Cash Flow: | 0 |
| Annual Sales: | $5.90 |
| Price / Book: | 0.1 |
Profitability
| EPS (TTM): | -27.73000 |
|---|---|
| Net Income (TTM): | $-11.38M |
| Gross Margin: | $2.04M |
| Return on Equity: | 0% |
| Return on Assets: | 0% |
Windtree Therapeutics Earnings Forecast
Key Windtree Therapeutics Financial Ratios
- The Gross Profit Margin over the past 22 years for WINT is 99.90%.
- The Selling, General & Administrative Expenses for WINT have been equal to 6,264.65% of Gross Profit Margin.
- The Interest Expense is -0.25% of Operating Income.
- Per Share Earnings over the last 29 years have been positive in 20 years.
Windtree Therapeutics Stock Price Chart
Industry, Sector and Symbol
| Stock Exchange: | NASDAQ |
|---|---|
| Industry: | Biotechnology |
| Sector: | Health Care |
| Current Symbol: | WINT |
| CUSIP: | 97382D |
| Website: | windtreetx.com |
Debt
| Debt-to-Equity Ratio: | 0 |
|---|---|
| Current Ratio: | 0 |
| Quick Ratio: | 0 |
Price-to-Earnings
| Trailing P/E Ratio: | 0 |
|---|---|
| Forward P/E Ratio: | 0 |
WINT Technical Analysis vs Fundamental Analysis
Sell
27
Windtree Therapeutics (WINT)
is a Sell
Is Windtree Therapeutics a Buy or a Sell?
-
Windtree Therapeutics stock is rated a Sell
The current Windtree Therapeutics [WINT] share price is $0.53. The Score for WINT is 27, which is 46% below its historic median score of 50, and infers higher risk than normal.